大麻酊剂在六个月内将背痛减轻了 30%，优于阿片类药物和安慰剂，其有希望的结果有待美国试验复制。 A cannabis tincture reduced back pain 30% over six months, outperforming opioids and placebos, with promising results pending U.S. trial replication.

发表在"自然医学"杂志上的两项欧洲研究表明,含有THC,CBD和其他化合物的大麻液比安慰剂更能缓解背痛,并且在六个月内比阿片类药物效果更好,胃肠道副作用更少. Two European studies published in Nature Medicine suggest a cannabis tincture containing THC, CBD, and other compounds provided better back pain relief than a placebo and outperformed opioids over six months with fewer gastrointestinal side effects. VER-01治疗导致12周后平均减少30%的疼痛,而安慰剂为20%,约有7名病人需要治疗,其中1人需要治疗。 The treatment, VER-01, led to a 30% average pain reduction after 12 weeks, compared to 20% with placebo, with about seven patients needing treatment for one to benefit. 虽然由于缺乏失明和样本规模小而受到限制,但专家们认为结果很有希望,反映了现实世界的使用情况,指出大麻没有表现出依赖或戒食,并允许正常运作。 Though limited by lack of blinding and small sample sizes, experts call the results promising and reflective of real-world use, noting cannabis showed no dependency or withdrawal and allowed normal functioning. 该产品预计将在几个欧洲国家获得核准,但美国林业发展局的核准正在等待美国试验的复制,使供应推迟多年。 The product is expected to gain approval in several European countries, but U.S. FDA approval is pending replication in American trials, delaying availability for years.